Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases
A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the…
Articles by Patricia Inácio, PhD
FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia
VistaGen Therapeutics will begin a Phase 2 clinical trial to evaluate its lead candidate AV-101 as a potential treatment…
High Blood Levels of Urate May Help Protect Dopamine-Producing Neurons in Men With Parkinson’s, Study Suggests
High levels of urate in the blood may help preserve dopamine-producing neurons and be used as a biomarker of positive…
Seelos Set to Begin Animal Studies for SLS-007 Using Gene Therapy Approach
Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for…
FDA Extends Abbott’s Infinity DBS System Approval to Target Additional Brain Region
The U.S. Food and Drug Administration (FDA) has expanded Abbott’s Infinity Deep Brain Stimulation (DBS) system approval to…
Case Report Describes Secondary Parkinsonism Due to Cavernoma in the Striatum
Secondary parkinsonism can be caused by a cavernoma — a cluster of abnormal blood vessels — located in a brain…
Biogen Acquires Pfizer’s PF-05251749, a Potential Disease-modifying Therapy for Parkinson’s, Alzheimer’s
Biogen is adding Pfizer’s PF-05251749 — a regulator of the body’s inner clock — to its group of potential…
Cannabinoids Ease Motor Symptoms in Mouse Model of Parkinson’s, Early Results Show
Cannabinoid-based formulations in development at GB Sciences were able to ease behavioral symptoms linked to the loss of dopamine…
Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease
Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for…
Gosuranemab Fails to Show Efficacy in Phase 2 Progressive Supranuclear Palsy Trial
Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating …